We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
19.00 | 1.07% | 1,799.50 | 1,796.00 | 1,796.50 | 1,799.50 | 1,780.00 | 1,784.00 | 9,804,173 | 16:35:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 15.00 | 73.94B |
Date | Subject | Author | Discuss |
---|---|---|---|
30/1/2019 23:17 | Oh dear....Mylan has just been given FDA approval for Advair generic. Mylan is up 7% and has added $1bn to its market capitalisation. That market cap must come from.GSK. I reckon a down day tomorrow, down more than 1% | zicopele | |
30/1/2019 17:00 | "zicopele 30 Jan '19 - 11:53 - 19002 of 19005 0 0 0 How is a breakup a solution to debt? Debt has to be repaid. Solution to debt is drug discoveries and that may include reducing dividend. Hopefully Tesaro will be successful as acquisition" Break up as in demerger I suspect of remaining business. Pack the majority of the debt on the segment with most regular cashflow able to service such and then see that segment sold to another Phamraceutucal company.. Remaining stand alone segment relatively debt fre, debt now another Pahrm Cos problem.. | wbecki | |
30/1/2019 13:31 | Sector rotation starting to take place. The pharmas should have a good run for a while. GSK and AZN powering ahead. | fuji99 | |
30/1/2019 12:42 | If there is any CGT payable as a result of presumed sale, that represents value destruction. A demerger has been intimated but debt is debt. New drugs are the solution. | zicopele | |
30/1/2019 11:57 | Presumably they believe that a breakup would be by a sale, rather than a share distribution. The proceeds used to pay off debt. | alphorn | |
30/1/2019 11:53 | How is a breakup a solution to debt? Debt has to be repaid. Solution to debt is drug discoveries and that may include reducing dividend. Hopefully Tesaro will be successful as acquisition. | zicopele | |
30/1/2019 09:13 | Tipped by Telegraph: Questor: "Glaxo’s breakup is a neat solution to its debt problem, so it’s time to buy back in" | tradermichael | |
30/1/2019 08:49 | Fantastic, they said 1 in 3 people will get shingles, massive market. I paid 130 pounds for a shingles vac.GSK double blockbuster on Shringlix I reckon. | montyhedge | |
30/1/2019 08:38 | Glaxo has seen strong growth momentum in its three new products — Trelegy Ellipta, Shingrix and Juluca – so far this year - each could become a blockbuster | tradermichael | |
30/1/2019 08:32 | Demand outstripping supply for shingles vac, what a great problem to have. Already blockbuster could we have double blockbuster coming years for that vaccine. | montyhedge | |
29/1/2019 18:00 | Yes lessons were learnt,good bittersweet memories,no regrets easy come easy go,that's life! | abdullla | |
29/1/2019 16:41 | Same here....I paid for a holiday on a company called eprime financial. Lost on scoot.com and Marconi. Remember John Mayo? | zicopele | |
29/1/2019 16:39 | Yeah, I made and lost a fortune on Scoot. | tradermichael | |
29/1/2019 16:21 | Crikey...Energis is a name from the past. Anyone remember the shill who used to shamelessly pump Sopheon? Those companies went pop in 2001. Scoot.com.is another beauty. | zicopele | |
29/1/2019 16:04 | Abdullla woz with TMF in the late sixties,these were the times of the disgraced Baltimore,Marconi and Energis all now are RIP! | abdullla | |
29/1/2019 15:40 | Long since given up with TMF Their articles are anodyne and generic - its a shame as back in the early days they used to offer some insight and the tips actually did quite well. I did have a few conversations with one of the better authors too. | dr biotech | |
29/1/2019 14:56 | Stupid article - the GSK network of local subsidiaries will ensure minimal impact of any loss of sales on the Continent for currently approved products. | alphorn | |
29/1/2019 13:59 | TMF is run by shysters. One says buy on a share and his colleague advises sell. | zicopele | |
29/1/2019 13:17 | A couple of snippets from TMF: See the recent relation of the share price to results announcements. The price has fallen between 1% and 3.5% on three of the previous four results days in the past year, but has recovered quickly thereafter. As far as Brexit,less than 30% of the companies’ revenues came from Europe in the last quarter, with the rest coming from the US and other international markets, helping to protect it from excessive exposure to a possibly-weaker UK or EU economy. | tradermichael | |
29/1/2019 12:59 | Our next quarterly dividend soon is 23p, dividend on the doormat every 13 weeks, I love GSK, lol. | montyhedge | |
29/1/2019 12:54 | Forward guidance not good. | zicopele | |
29/1/2019 12:52 | They beat on earnings, beat on sales, investors always want more, lol. | montyhedge | |
29/1/2019 12:50 | PFE is down in the premarket | zicopele | |
29/1/2019 11:49 | Good figures and they beat analyst forecasts, just out from Pfzier bodes well for the sector. | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions